患者手术数据

数据集获取（Figshare）

• 源站标题：Surgical data of the patients.
• DOI：10.1371/journal.pone.0333891.t002
• 发布日期：2025-12-12
• 文件数：1 个
• 文件总体积：9.73 KB
• 源站页面：https://plos.figshare.com/articles/dataset/Surgical_data_of_the_patients_/30873101

命令行下载

curl -L -o "Table 2.xls" "https://ndownloader.figshare.com/files/60329576"

文件清单

• Table 2.xls（9.73 KB）

文件总体积 9.73 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

Objectives
Tricuspid valve repair, particularly with annuloplasty rings, is increasingly recognized as an effective treatment. PM-AR-T is a semi-rigid annuloplasty ring based on a nickel-titanium alloy which has made progress in animal models, however, studies on PM-AR-T’s performance in patients with tricuspid regurgitation (TR) are lacking. This study aimed to compare the efficacy and safety of the PM-AR-T with the Edwards MC3 ring for the TR treatment.
Methods
A non-inferiority, randomized controlled trial was conducted in 20 centers across China, enrolling patients with tricuspid valve disease requiring surgical repair. Patients were randomized to receive either PM-AR-T or Edwards MC3 ring. The primary endpoint was the success rate of valve repair at 6 months.
Results
A total of 164 patients underwent valve annuloplasty, 83 and 81 in the PM-AR-T and Edwards MC3 groups. Valve repair success rates were 92.8% and 93.8% in the PM-AR-T and Edwards MC3 groups, demonstrating non-inferiority with a difference of −1.1% (95% confidence interval [CI]: −9.5 to 7.4), which was less than the pre-specified non-inferiority margin of −10%. No significant intergroup differences were found in valve regurgitation, echocardiographic parameters, and New York Heart Association (NYHA) functional classification at any postoperative time point. At 12 months, the proportions of patients without regurgitation were comparable, 30.4% and 27.8% in the PM-AR-T and Edwards MC3 groups (P = 0.705). Improvement to NYHA functional class I status was detected in 46.2% and 45.6% of the two groups by 12 months (P = 0.893). Both rings exhibited comparable safety profiles, with no device-related serious adverse events, cardiovascular deaths, major bleeding events, severe structural damage, infective endocarditis, or thromboembolic events.
Conclusions
The PM-AR-T tricuspid valve semi-rigid ring is effective in improving TR, demonstrating non-inferiority to the Edwards MC3 ring, with a favorable safety profile.
Clinical Trial Registration: This study was registered at Chinese Clinical Trial Registry (ChiCTR2100043007).

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.1371/journal.pone.0333891.t002（source: https://plos.figshare.com/articles/dataset/Surgical_data_of_the_patients_/30873101）。